PHLDB3

Across TCGA pan-cancer cohorts, PHLDB3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PHLDB3 data layer compared with 29 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PHLDB3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PHLDB3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PHLDB3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.807	0.468	.001	38	view →
LUAD	OS	Median	II,III,IV	0.712	1.000	.017	20	view →
CCRCC	DFS	Tertile	II,III,IV	0.425	1.000	.016	12	view →
LSCC	DFS	Median	II,III,IV	0.833	0.541	.011	10	view →
PDAC	OS	Tertile	III,IV	0.228	0.797	.026	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PHLDB3–HNSC (DFS)

Open the HNSC breakdown →